Patents by Inventor Kerstin Sautter

Kerstin Sautter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9045776
    Abstract: The invention relates to DNA-sequences, especially transcription- or expression-enhancing elements (TE elements) and their use on an expression vector in conjunction with an enhancer, a promoter, a product gene and a selectable marker. TE elements bring about an increase in the expression of the product gene, particularly when stably integrated in the eukaryotic genome, preferably the CHO-DG44 genome.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: June 2, 2015
    Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Barbara Enenkel, Kerstin Sautter
  • Patent number: 8338179
    Abstract: The invention relates to modified neomycin phosphotransferase genes and their use in a selection method for high-producing recombinant cells. The invention further relates to expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter and a method of preparing heterologous gene products using these expression vectors.
    Type: Grant
    Filed: January 4, 2008
    Date of Patent: December 25, 2012
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Barbara Enenkel, Juergen Fieder, Ralf Otto, Kerstin Sautter, Klaus Bergemann
  • Publication number: 20110281301
    Abstract: The invention concerns the field of protein production and cell culture technology. It describes a method of producing a heterologous protein of interest in a cell comprising a. Increasing the expression or activity of a secretion enhancing gene, and b. Increasing the expression or activity of an anti-apoptotic gene, and c. Effecting the expression of said protein of interest, whereby the secretion enhancing gene is a gene encoding a protein whose expression or activity is induced during one of the following cellular processes: plasma-cell differentiation, unfolded protein response (UPR), endoplasmic reticulum overload response (EOR).
    Type: Application
    Filed: October 6, 2008
    Publication date: November 17, 2011
    Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG
    Inventors: Hitto Kaufmann, Eric Becker, Lore Florin, Barbara Enenkel, Kerstin Sautter, Rebecca Bischoff
  • Publication number: 20100311121
    Abstract: The invention relates to DNA-sequences, especially transcription- or expression-enhancing elements (TE elements) and their use on an expression vector in conjunction with an enhancer, a promoter, a product gene and a selectable marker. The invention describes Sequence No. 1 and TE elements TE-01, -02, -03, -04, -06, -07, -08, -10, -11 or -12. Because of their small size, TE-06, TE-07 or TE-08 are particularly preferred. Sequence No. 1 originates from a sequence region located upstream from the coding region of the Ub/S27a gene from CHO cells. TE elements bring about an increase in the expression of the product gene, particularly when stably integrated in the eukaryotic genome, preferably the CHO-DG44 genome. Chromosomal positional effects are thereby overcome, shielded or cancelled out. In this way the proportion of high producers in a transfection mixture and also the absolute expression level are increased up to seven-fold.
    Type: Application
    Filed: July 23, 2010
    Publication date: December 9, 2010
    Applicant: Boehringer Ingelheim Pharma GmbH & Co.KG
    Inventors: Barbara ENENKEL, Kerstin SAUTTER
  • Patent number: 7732181
    Abstract: The invention relates to modified neomycin phosphotransferase genes and their use in a selection method for high-producing recombinant cells. The invention further relates to expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter and a method of preparing heterologous gene products using these expression vectors.
    Type: Grant
    Filed: January 4, 2008
    Date of Patent: June 8, 2010
    Assignee: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Barbara Enenkel, Juergen Fieder, Ralf Otto, Kerstin Sautter, Klaus Bergemann
  • Publication number: 20080187953
    Abstract: The invention relates to modified neomycin phosphotransferase genes and their use in a selection method for high-producing recombinant cells. The invention further relates to expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter and a method of preparing heterologous gene products using these expression vectors.
    Type: Application
    Filed: January 4, 2008
    Publication date: August 7, 2008
    Inventors: Barbara ENENKEL, Juergen Fieder, Ralf Otto, Kerstin Sautter, Klaus Bergemann
  • Publication number: 20080131969
    Abstract: The invention relates to modified neomycin phosphotransferase genes and their use in a selection method for high-producing recombinant cells. The invention further relates to expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter and a method of preparing heterologous gene products using these expression vectors.
    Type: Application
    Filed: January 4, 2008
    Publication date: June 5, 2008
    Inventors: Barbara ENENKEL, Juergen Fieder, Ralf Otto, Kerstin Sautter, Klaus Bergemann
  • Publication number: 20080124760
    Abstract: The invention relates to DNA-sequences, especially transcription- or expression-enhancing elements (TE elements) and their use on an expression vector in conjunction with an enhancer, a promoter, a product gene and a selectable marker. The invention describes Sequence No. 1 and TE elements TE-01, -02, -03, -04, -06, -07, -08, -10, -11 or -12. Because of their small size, TE-06, TE-07 or TE-08 are particularly preferred. Sequence No. 1 originates from a sequence region located upstream from the coding region of the Ub/S27a gene from CHO cells. TE elements bring about an increase in the expression of the product gene, particularly when stably integrated in the eukaryotic genome, preferably the CHO-DG44 genome. Chromosomal positional effects are thereby overcome, shielded or cancelled out. In this way the proportion of high producers in a transfection mixture and also the absolute expression level are increased up to seven-fold.
    Type: Application
    Filed: June 13, 2007
    Publication date: May 29, 2008
    Inventors: Barbara Enenkel, Kerstin Sautter
  • Patent number: 7344886
    Abstract: The invention relates to modified neomycin phosphotransferase genes and their use in a selection method for high-producing recombinant cells. The invention further relates to expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter and a method of preparing heterologous gene products using these expression vectors.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: March 18, 2008
    Assignee: Boehringer Ingelheim Pharma GmbH & Co., KG
    Inventors: Barbara Enenkel, Juergen Fieder, Ralf Otto, Kerstin Sautter, Klaus Bergemann
  • Publication number: 20050106580
    Abstract: The invention relates to modified neomycin phosphotransferase genes and their use in a selection method for high-producing recombinant cells. The invention further relates to expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter and a method of preparing heterologous gene products using these expression vectors.
    Type: Application
    Filed: November 26, 2003
    Publication date: May 19, 2005
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Barbara Enenkel, Juergen Fieder, Ralf Otto, Kerstin Sautter, Klaus Bergemann